Pregestational Cardiometabolic Biomarkers and Future Hypertensive Disorders of Pregnancy - Summary - MDSpire

Pregestational Cardiometabolic Biomarkers and Future Hypertensive Disorders of Pregnancy

  • By

  • Angelika Qvick

  • Anna Sandström

  • Anna Norhammar

  • Max Vikström

  • Anna-Clara Spetz Holm

  • Rebecka Hultgren

  • Niklas Hammar

  • Karin Leander

  • April 30, 2026

  • 0 min

Share

Objective:

To investigate pregestational cardiometabolic disturbances and their association with hypertensive disorders of pregnancy (HDP) in nulliparous women, highlighting the significance of addressing rising HDP rates.

Key Findings:
  • HDP affects 5% to 15% of pregnancies and poses long-term cardiovascular risks, emphasizing the need for early identification.
  • Pregestational cardiometabolic disturbances may be linked to increased risk of HDP, suggesting a need for targeted interventions.
  • Elevated fasting glucose and triglyceride levels, along with reduced HDL-C, were noted as potential risk factors, warranting further investigation.
Interpretation:

Identifying cardiometabolic risk factors before conception could enhance prevention strategies for HDP, potentially leading to improved maternal and neonatal outcomes.

Limitations:
  • Variability in study design and biomarker thresholds may affect findings, and potential biases in data collection should be considered.
  • The study primarily included older nulliparous women, limiting generalizability to younger populations.
Conclusion:

A stronger evidence base for early prevention of HDP is needed, focusing on pregestational cardiometabolic health and the importance of early intervention.

Original Source(s)

Related Content